Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 158

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 158
---
 provision where we have a present obligation, whether legal or constructive, as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and a reliable estimate can be made of the amount of the outflow of resources. We also disclose a contingent liability in circumstances where we are unable to make a reasonable estimate of the expected financial effect that will result from the ultimate resolution of the proceeding, or a cash outflow is not probable. For additional details regarding the financial impact of provisions for risks see Notes D.19.3. “Other provisions” and D.22. “Legal and Arbitral Proceedings” to our consolidated financial statements included at Item 18. of this annual report. 7/ Provisions for restructuring costs Provisions for restructuring costs include collective redundancy or early retirement benefits, compensation for early termination of contracts, and rationalization costs relating to restructured sites. Refer to Note D.19.2. to our consolidated financial statements included at Item 18. of this annual report. Provisions are estimated on the basis of events and circumstances related to present obligations at the end of the reporting period and of past experience, and to the best of management’s knowledge at the date of preparation of the financial statements. The assessment of provisions can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. Given the inherent uncertainties related to these estimates and assumptions, the actual outflows resulting from the realization of those risks could differ from our estimates.

| SANOFIFORM 20-F2024 | 71 |

| PART I                                               |
| ITEM 5. Operating and Financial Review and Prospects |

A.2. Results of operations Year ended December 31, 2024 compared with year ended December 31, 2023 Consolidated income statements

| (€ million)                                                                  |    2024 | as % of netsales | 2023(a) | as % of netsales |
| Net sales                                                                    |  41,081 | 100.0%           |  37,817 | 100.0%           |
| Other revenues                                                               |   3,205 | 7.8%             |   3,801 | 10.1%            |
| Cost of sales                                                                | -13,205 | -32.1%           | -12,628 | -33.4%           |
| Gross profit                                                                 |  31,081 | 75.7%